Chronic Myeloproliferative Disorders Completed Phase Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00053157Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic AnemiaSupportive Care